lp-a.org

Statins

Adding Lp(a) to PREVENT risk equations increases statin eligibility in low-risk adults (Am Heart J Plus 2026)

Original title: Lipoprotein(a) and statin indications in low-risk patients based on the 2026 ACC/AHA dyslipidemia guideline

Am Heart J Plus · · 6

Faridi KF, Wu Q, Spatz ES, Desai NR, Lu Y

This cohort study applied the PREVENT equations to low-risk adults to assess how incorporating Lp(a) alters statin eligibility. Among 124 patients with measured Lp(a) and 28,527 with imputed values, adding Lp(a) to 10-year risk calculations newly designated 3.3% of those with levels ≥125 nmol/L as statin eligible, compared with 0.1% in the imputed group. Exploratory 30-year risk modelling increased eligibility to 20.2%, with 70.0-84.6% of the measured cohort meeting thresholds at the highest Lp(a) quintile. Integrating Lp(a) into standard risk equations meaningfully reclassifies therapy indications in asymptomatic populations, though reliance on imputed values and exploratory long-term modelling limits immediate clinical translation.

Read the paper (DOI)PubMed

Original abstract

Background: Though elevated lipoprotein (a) (Lp[a]) is associated with ASCVD and testing is recommended for all adults, how to use Lp(a) for decision-making in low-risk patients remains uncertain.

Methods: We studied low-risk adults in a large healthcare system, excluding those on statins or with statin indications in the 2026 ACC/AHA dyslipidemia guideline. ASCVD risk and statin eligibility were estimated using the PREVENT equations, incorporating Lp(a) using a calculation proposed by the AHA: ASCVD risk x (1.11^[(Lp[a] in nmol/L)/50]). Measured Lp(a) was used when available, and imputed values were used for all other adults.

Results: The cohort included 124 low-risk patients with measured Lp(a) (median [25th-75th percentile] age 44 [38-50] years; 64.5% women) and 28,527 without Lp(a) (median age 42 [36-49] years, 73.3% women). Adding Lp(a) to 10-year risk equations made 3.3% of patients with measured Lp(a) ≥125 nmol/L and 0.1% with imputed Lp(a) of 125 nmol/L newly statin eligible. Eligibility rose with older age, higher Lp(a), and higher ASCVD risk. When Lp(a) was added to 30-year risk in exploratory analyses, 20.2% with measured Lp(a) and 19.6% with imputed Lp(a) of 125 nmol/L met statin eligibility, and 70.0-84.6% (measured cohort) and 33.1-54.2% (imputed cohort) at the highest Lp(a) quintile met eligibility as age increased.

Conclusions: Integrating Lp(a) into ASCVD risk equations changes predicted risk and potential statin eligibility in low-risk adults not indicated for therapy under current guidelines. Including Lp(a) in risk estimation and clinical decision-making, particularly for patients with elevated levels, could be considered in patients with low ASCVD risk.

epidemiologyguidelinesrisk predictionstatinstesting

Summary written by lp-a.org from the published abstract; figures as published. Page updated 6 November 2026. Methods.